FAP and neoplasm: Comparative therapy studies using all four radiopharmaceuticals demonstrated that when compared to the isotype control radiopharmaceutical [177Lu]Lu-CHX-A”-DTPA-A33, which produced a median cohort survival of 32 d, all three anti-FAP antibodies delayed tumor growth, with the median survival of animals receiving [177Lu]Lu-CHX-A”-DTPA-F19 being 32 d, and greater than 43 d for [177Lu]Lu-CHX-A”-DTPA-ESC14 and [177Lu]Lu-CHX-A”-DTPA-ESC11.